Orf Virus

Overview and Taxonomy of Orf Virus

Taxonomic Classification and Phylogenetic Position

Orf virus (ORFV) is the prototypical and most extensively characterized member of the genus Parapoxvirus within the subfamily Chordopoxvirinae of the family Poxviridae [3, 24]. This taxonomic placement situates ORFV among a diverse group of large, enveloped, double-stranded DNA viruses that replicate exclusively within the cytoplasm of infected cells. The genus Parapoxvirus is distinguished from other poxvirus genera, such as Orthopoxvirus (which includes vaccinia virus and variola virus) and Capripoxvirus, by a unique combination of virion morphology, genomic characteristics, and host range restrictions. The World Organisation for Animal Health (WOAH) recognizes ORFV as the causative agent of contagious ecthyma (also known as contagious pustular dermatitis or sore mouth), a disease of significant economic importance to small ruminant industries globally. The virus is also classified as a zoonotic pathogen by the World Health Organization (WHO), capable of causing self-limiting but clinically distinctive skin lesions in humans who have direct contact with infected animals or contaminated fomites [4, 10, 29].

Phylogenetic analyses based on multiple genomic loci, including the major envelope protein gene (B2L, ORFV011) and the F1L gene (ORFV059), have consistently demonstrated that ORFV isolates form a monophyletic clade within the parapoxviruses, clearly separable from other parapoxvirus species such as bovine papular stomatitis virus (BPSV) and pseudocowpox virus (PCPV) [16, 21, 30]. Within the ORFV clade, substantial genetic heterogeneity exists, with isolates often clustering according to geographic origin and, intriguingly, according to host species. Comparative genomic studies have revealed that sheep-derived and goat-derived ORFV strains form distinct phylogenetic branches with robust bootstrap support, suggesting a degree of host adaptation that may influence viral transmission dynamics and pathogenicity [25]. This host-associated clustering is supported by the identification of 33 unique amino acid residues in gene 008 that differentiate sheep-origin from goat-origin isolates, providing a molecular signature for host-specific adaptation [25]. The genetic diversity among ORFV strains is further underscored by the presence of extensive microsatellite variation across the genome, with 1,036–1,181 simple sequence repeats identified per strain, predominantly dinucleotide repeats (76.9%), which serve as valuable markers for molecular epidemiology and evolutionary studies [8].

Virion Morphology and Physicochemical Properties

The ORFV virion exhibits a distinctive ovoid or cylindrical morphology that is characteristic of the parapoxviruses, in contrast to the brick-shaped or pleomorphic virions of orthopoxviruses. Atomic force microscopy of purified ORFV particles has confirmed this typical ovoid shape, with dimensions approximately 260–300 nm in length and 160–190 nm in width [32]. The virion surface displays a unique crisscross pattern of tubular filaments, a feature that is diagnostically useful for electron microscopic identification. The virus is enveloped, with a lipid bilayer derived from the host cell membrane, and contains a complex core structure housing the linear double-stranded DNA genome.

The physicochemical stability of ORFV has been systematically characterized, revealing a robust virion that can withstand a range of environmental stresses. The isoelectric point of the ORFV genotype D1707-V has been determined to be approximately pH 3.5, indicating a highly acidic surface charge that influences interactions with chromatographic matrices and potentially with host cell surfaces [1, 7]. The virus maintains stable infectivity across a pH range of 5.0 to 7.4, with buffering substances such as TRIS, HEPES, and phosphate-buffered saline having no detrimental effect [1]. Ionic strength up to 0.5 M NaCl or MgCl₂ does not compromise viral stability, although ammonium chloride causes significant destabilization [1]. Short-term thermal stress of up to 37°C for two days and repeated freeze-thaw cycles (up to 20 cycles) do not substantially reduce infectivity, underscoring the remarkable environmental resilience of ORFV [1]. The virus exhibits low shear sensitivity when subjected to peristaltic pumping or mixing, although ultrasonication is highly detrimental [1]. These stability characteristics have profound implications for viral transmission, as ORFV can persist in scabs and environmental fomites for extended periods, facilitating both direct and indirect transmission routes.

Genomic Architecture and Unique Genetic Features

The ORFV genome is a linear, double-stranded DNA molecule of approximately 132–139 kilobase pairs (kbp), with a high guanine-plus-cytosine (G+C) content of approximately 64%, a feature that distinguishes it from many other poxviruses [24, 25]. The genome is characterized by inverted terminal repeats (ITRs) and covalently closed hairpin loops at each terminus, a common feature among poxviruses that facilitates genome replication and packaging. The central region of the genome is highly conserved and contains genes essential for viral replication, transcription, and virion assembly, many of which share homology with vaccinia virus and other chordopoxviruses [24]. In contrast, the terminal regions are more variable and encode a suite of unique genes that mediate host range, immunomodulation, and pathogenesis.

The ORFV genome encodes approximately 124 to 132 genes, depending on the strain, with the variability largely attributable to gene content differences in the terminal regions [24, 25]. Comparative genomic analyses of four Fujian goat ORFV strains (OV-GO, OV-YX, OV-NP, and OV-SJ1) revealed that OV-NP lacked seven genes and OV-SJ1 lacked three genes near the right terminus compared to other ORFVs, and these deletions correlated with reduced virulence in goats, suggesting that gene loss can lead to attenuation [25]. This genomic plasticity is a hallmark of ORFV evolution and has been exploited for the development of attenuated vaccine strains, most notably the D1701-V strain. The D1701-V variant, which was adapted for growth in Vero cells, underwent major genomic changes including the deletion of seven open reading frames (ORF008, ORF101, ORF102, ORF114, ORF115, ORF116, and ORF117) compared to its predecessor strain D1701-B [12]. These deletions have rendered D1701-V highly attenuated while retaining excellent immunogenicity, making it a safe and effective viral vector platform for recombinant vaccine development [9, 12, 28].

One of the most remarkable aspects of ORFV genomics is the presence of multiple genes that have been acquired from the host genome through horizontal gene transfer, a process known as gene capture. Phylogenetic analyses strongly suggest that both the viral interleukin-10 (vIL-10) gene and the vascular endothelial growth factor (VEGF) gene were captured from their respective host ancestors during the evolution of the parapoxviruses [24]. The vIL-10 homologue (ORFV127) is a potent immunomodulator that suppresses pro-inflammatory cytokine production and contributes to the virus's ability to repeatedly infect its host despite the presence of specific immunity [5, 24]. Similarly, the VEGF homologue (ORFV132) promotes angiogenesis and contributes to the proliferative nature of orf lesions [24, 32]. Other unique immunomodulatory genes include a chemokine binding protein (CBP, ORFV112) and a granulocyte-macrophage colony-stimulating factor/interleukin-2 binding protein (GIF, ORFV117), both of which appear to have evolved from a common poxvirus ancestral gene rather than being directly captured from the host [24]. Additionally, ORFV encodes three distinct inhibitors of the nuclear factor-κB (NF-κB) signaling pathway, which have no homology to any known NF-κB inhibitors, representing a novel class of viral immune evasion molecules [24]. The B2L gene (ORFV011), encoding the major envelope protein, has been identified as a potent immunomodulator that elicits immune cell accumulation at sites of inoculation and can serve as an adjuvant for antigen-specific responses [31].

Host Range, Zoonotic Potential, and Epidemiological Significance

ORFV exhibits a broad host range among artiodactyls, with sheep and goats serving as the primary natural reservoirs and the most clinically affected species [3, 15, 18]. However, the virus is capable of infecting a wide array of wild and domestic ruminants, including cattle, camels, reindeer, muskoxen, caribou, and various deer species [13, 17, 27]. Serological and molecular surveys have documented ORFV infection in mountain goats, Dall's sheep, muskoxen, Sitka black-tailed deer, and caribou in Alaska, demonstrating that the virus circulates in wildlife populations across diverse geographic regions [17]. In Turkey, ORFV was identified as the cause of proliferative skin lesions in cattle, with B2L gene sequences showing 100% identity to Turkish field isolates from goats, indicating cross-species transmission from goats to cattle [13]. Similarly, ORFV infection has been confirmed in Japanese serows (Capricornis crispus), a wild goat-like bovid endemic to Japan, where the virus has been continuously prevalent in the population [23].

The zoonotic potential of ORFV is well-documented, with human infections occurring through direct contact with infected animals or contaminated fomites [4, 10, 11, 29]. The Centers for Disease Control and Prevention (CDC) recognizes orf as an occupational zoonosis affecting farmers, veterinarians, slaughterhouse workers, and butchers. However, infections also occur in individuals without occupational risk factors through cultural or religious practices, such as the slaughter of sheep during Eid al-Adha, the Muslim Feast of Sacrifice [10, 29]. Human orf typically presents as a solitary, 1-cm pustular or nodular lesion on the hands or fingers, which is self-limiting and resolves over several weeks without specific treatment [4]. Complications can include erythema multiforme, a hypersensitivity reaction that occurs in a subset of patients and may be mediated by host immune responses to viral antigens [26]. Severe or atypical presentations have been reported, including infection in a thermal-burn patient at both the skin-graft harvest and recipient sites, highlighting the potential for ORFV to exploit disrupted epithelial barriers [22].

The epidemiology of ORFV is characterized by its global distribution and endemicity in small ruminant populations worldwide. The World Organisation for Animal Health (WOAH) notes that orf is not a notifiable disease in many countries, leading to underreporting and a lack of comprehensive surveillance data. Seroprevalence studies have revealed high infection rates in endemic regions; for example, a study in Terengganu, Malaysia, found an overall seroprevalence of 22.8% among sheep and goats, with 25.1% of goats and 16.8% of sheep seropositive [14]. In Ethiopia, molecular screening of 400 animals detected ORFV DNA in 12% of samples, with higher prevalence in sheep compared to goats, and in animals with poor body condition, extensive management systems, and a history of outbreaks [20]. The virus is capable of causing significant morbidity and mortality, particularly in young lambs and kids, where lesions can interfere with feeding and lead to secondary bacterial infections and death [15].

Transmission Dynamics and Environmental Persistence

ORFV is traditionally considered to be transmitted through direct contact between infected and susceptible animals, with virus-laden scabs and lesion exudates serving as the primary sources of infectious material [6, 15]. However, recent evidence has challenged this paradigm by demonstrating alternative transmission routes. Infectious ORFV has been isolated from the saliva and milk of asymptomatic dairy goats, and inoculation of these isolates into ORFV-free goats induced typical orf lesions [2]. This finding indicates that subclinically infected animals can shed virus in bodily secretions, potentially facilitating transmission through contaminated feed, water, or milking equipment. Similarly, ORFV DNA has been detected in the blood of asymptomatic goats, and blood-derived isolates were infectious and capable of inducing disease upon experimental inoculation [19]. These observations suggest that viremic animals may serve as silent carriers, contributing to the maintenance and spread of the virus within herds.

The role of mechanical vectors in ORFV transmission has been experimentally investigated. The common house fly, Musca domestica, was shown to pick up ORFV DNA from contaminated scab homogenates and transmit it to contact surfaces, with 100% of flies capable of carrying the viral genome and 60% testing positive in both crop and excreta samples [6]. These findings implicate flies as potential mechanical vectors that could contribute to the rapid spread of ORFV within and between farms, particularly in intensive management systems where fly populations are high.

The remarkable environmental stability of ORFV further enhances its transmissibility. The virus can remain infectious in dried scabs for months, particularly under cool and dry conditions, and is resistant to many common disinfectants [1]. This persistence allows ORFV to survive on contaminated equipment, fencing, feed troughs, and bedding, facilitating indirect transmission even in the absence of direct animal-to-animal contact. The ability of the virus to withstand repeated freeze-thaw cycles and temperatures up to 37°C for extended periods [1] ensures its survival in a variety of climatic conditions, from cold mountainous regions to temperate lowlands.

Immunomodulation and the Capacity for Reinfection

A defining characteristic of ORFV infection is its ability to repeatedly infect both previously infected and vaccinated animals, a phenomenon that has puzzled researchers and frustrated control efforts for decades [3, 15, 18]. This capacity for reinfection is attributable to the arsenal of immunomodulatory genes encoded by the virus, which temporarily suppress host immunity and create a window of vulnerability for subsequent infections. The viral immunomodulators target multiple arms of the host immune response, including innate inflammatory pathways, cytokine signaling, and antigen presentation.

The vIL-10 homologue (ORFV127) is a key player in this immune evasion strategy, suppressing the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-12 (IL-12), thereby dampening the Th1-type immune response that is critical for viral clearance [5, 24]. The chemokine binding protein (CBP, ORFV112) sequesters chemokines, preventing the recruitment of inflammatory cells to the site of infection [5, 24]. The GIF protein (ORFV117) binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2), further inhibiting the activation and proliferation of immune effector cells [5, 24]. Additionally, ORFV interferes with major histocompatibility complex class I (MHC I) surface expression by disrupting the vesicular transport machinery and inducing fragmentation of the Golgi apparatus, thereby reducing the presentation of viral antigens to cytotoxic T lymphocytes [33]. This multifaceted immune subversion allows ORFV to replicate and spread despite the presence of a specific immune response, and it explains why natural infection does not confer long-lasting protective immunity.

The implications of this immunomodulatory capacity are profound for vaccine development. Commercially available live

Molecular Pathogenesis of Orf Virus

Genomic Architecture and the Basis for Immune Evasion

The molecular pathogenesis of Orf virus (ORFV) is fundamentally rooted in its unique genomic composition and the sophisticated arsenal of immunomodulatory proteins (IMPs) it encodes. As the prototype species of the Parapoxvirus genus within the Poxviridae family, ORFV possesses a double-stranded DNA genome approximately 138 kbp in size, characterized by a high G+C content (~64%) and encoding 132 genes [24]. A defining feature of ORFV pathogenesis, distinguishing it from many other poxviruses, is its strict epitheliotropism and its remarkable capacity to repeatedly infect both previously infected and vaccinated hosts [3, 35]. This ability to circumvent established host immunity is not a sign of viral weakness but rather a testament to a highly evolved molecular strategy centered on the temporal and spatial manipulation of the host's innate and adaptive immune responses. The genome is organized with a central conserved core region, housing genes essential for replication and structural integrity, flanked by variable terminal regions that are the primary repositories for these virulence and host-range determinants [24, 25]. The specific deletions and rearrangements in these terminal regions, particularly in attenuated vaccine strains such as D1701-V, which lacks seven open reading frames (including ORF008, ORF101, ORF102, ORF114-117) found in its pathogenic predecessor, directly correlate with a reduction in virulence, underscoring the critical role these loci play in pathogenesis [12, 25].

The Immunomodulatory Arsenal: Subverting Host Defenses at the Molecular Level

ORFV's pathogenic success is largely attributable to a multi-pronged attack on the host immune system, mediated by a suite of proteins that target key signaling pathways from the site of infection in the epidermis. The World Organisation for Animal Health (WOAH) recognizes orf as a significant transboundary disease, and the molecular basis for its tenacity is a major area of study.

Interception of Cytokine and Chemokine Networks: A critical component of the ORFV immunomodulatory strategy involves the direct sequestration of pro-inflammatory cytokines and chemokines. The viral chemokine binding protein (CBP, encoded by ORFV112) and the inhibitor of granulocyte-monocyte colony-stimulating factor and IL-2 (GIF, encoded by ORFV117) are prime examples [5, 24]. CBP functions by binding to a broad spectrum of chemokines, effectively neutralizing the chemotactic gradient that would otherwise recruit neutrophils, macrophages, and lymphocytes to the site of infection. Similarly, GIF binds with high affinity to GM-CSF and IL-2, two cytokines pivotal for the activation and proliferation of macrophages and T-cells, respectively. The in vivo significance of these proteins is demonstrated by the fact that recombinant ORFV strains individually deleted for these genes (ΔCBP, ΔGIF) show a marked reduction in virulence, with lesions regressing significantly faster and virus shedding ceasing earlier compared to infection with the parental wild-type virus [5].

Viral Orthologs of Host Cytokines: vIL-10 and VEGF-E: Perhaps the most elegant example of molecular mimicry is the ORFV-encoded interleukin-10 homologue (vIL-10, ORFV127) and vascular endothelial growth factor (VEGF-E, ORFV132). Phylogenetic analysis strongly suggests these genes were ‘captured’ from the host genome during the evolutionary history of the parapoxviruses [24]. vIL-10 shares significant structural and functional homology with host IL-10, a potent anti-inflammatory cytokine. By mimicking IL-10, vIL-10 suppresses the expression of pro-inflammatory cytokines such as IL-1, TNF-α, and IL-8, and inhibits the function of antigen-presenting cells and T-cells, thereby dampening the Th1-driven antiviral response [24, 35]. This is complemented by the action of VEGF-E, a viral growth factor that is a potent inducer of vascular permeability and angiogenesis. VEGF-E binds specifically to VEGF receptor-2 (VEGFR-2), driving the extensive proliferation of endothelial cells and blood vessels that underlies the proliferative, papillomatous nature of orf lesions [24, 34]. This robust angiogenesis not only provides nutrients for the expanding lesion but also creates a highly vascularized environment that may facilitate viral dissemination and contribute to the chronic, often exuberant, granulation tissue characteristic of the disease [34].

Subversion of Antigen Presentation and Cellular Signaling

Beyond cytokine mimicry, ORFV employs direct intracellular mechanisms to cripple the host's ability to recognize and eliminate infected cells.

Interference with MHC Class I Presentation: A hallmark of viral immune evasion is the downregulation of Major Histocompatibility Complex Class I (MHC I) molecules, a strategy that impairs cytotoxic T lymphocyte (CTL) recognition. ORFV accomplishes this through a highly specific and disruptive process. Infection leads to a structural disruption and fragmentation of the Golgi apparatus, the central hub for protein trafficking and modification [33]. This physical disruption impairs the vesicular transport of MHC I molecules from the endoplasmic reticulum (ER) to the cell surface. Consequently, a significant reduction, up to 50%, in MHC I surface expression is observed in infected cells [33]. This blockade is associated with early viral gene expression and is accompanied by aberrant carbohydrate trimming of post-ER MHC I molecules. The remaining MHC I population on the cell surface exhibits an extended half-life, suggesting a complex, multi-faceted mechanism potentially involving both early and late viral gene products to ensure that infected cells remain ‘invisible’ to CTLs for as long as possible [33].

Manipulation of the NF-κB and p53 Pathways: ORFV encodes three distinct inhibitors of the nuclear factor (NF)-κB signaling pathway, a master regulator of the inflammatory response [24]. These inhibitors, which have no homology to other known NF-κB inhibitors, act at different points within the signaling cascade to prevent the transcription of pro-inflammatory cytokines and interferons. This ensures that the early innate immune response is significantly blunted. Concurrently, transcriptomic analysis of human foreskin fibroblast cells infected with ORFV reveals a profound modulation of host gene expression, including the activation of the p53 signaling pathway to induce apoptosis at 8 hours post-infection, while paradoxically also promoting cell cycle progression [36]. This intricate balance between apoptosis and proliferation is likely orchestrated by viral gene products like the anaphase-promoting complex homologue, which is believed to manipulate the cell cycle to create an environment favorable for viral DNA synthesis within the terminally differentiating keratinocytes of the skin [24]. This manipulation results in the characteristic proliferative pathology of the lesion.

Pathogenic Consequences: From Asymptomatic Carriage to Lesion Pathology

The molecular interplay described above has direct consequences for disease manifestation and transmission. The immunomodulation is so effective that it can permit a state of asymptomatic carriage, a discovery of profound epidemiological significance. Infectious ORFV has been isolated from the saliva and milk of dairy goats without any clinical signs, demonstrating that subclinically infected animals can serve as silent reservoirs for viral shedding [2]. Similarly, the detection of ORFV DNA in the blood of asymptomatic goats suggests a potential for systemic or hematogenous spread, challenging the traditional view of orf as a purely localized, epitheliotropic infection [19]. This ability to establish a subclinical or persistent infection is a direct consequence of the viral arsenal that dampens immune recognition and inflammation.

When clinical disease does manifest, it is the net result of the virus’s molecular activities. The initial lesion begins with viral entry and replication in epidermal keratinocytes. The viral VEGF-E drives rapid keratinocyte proliferation and profound angiogenesis, producing the classic proliferative scab and papillomatous growth [24, 34]. Concurrently, vIL-10 and the NF-κB inhibitors suppress the acute inflammatory response, allowing the lesion to enlarge. The chemokine and cytokine binding proteins (CBP, GIF) prevent the timely recruitment of effector immune cells [5]. The downregulation of MHC I protects infected cells from CTL-mediated killing, prolonging the infection [33]. This complex orchestration results in a disease that is typically self-limiting but can persist for weeks, is prone to recurrence, and can be severe, especially in young animals where mortality can be high [3, 15]. The molecular heterogeneity observed among ORFV isolates from different geographic regions and host species, particularly in the immunomodulatory genes, likely accounts for the wide spectrum of virulence and host range, from the benign self-limiting lesions in sheep to more severe disease in goats, cattle, and wildlife such as mountain goats and Dall’s sheep [13, 17, 25, 32, 37].

Epidemiology and Zoonotic Transmission of Orf Virus

Global Distribution and Host Range

Orf virus (ORFV), the prototype species of the genus Parapoxvirus within the family Poxviridae, exhibits a truly global distribution, with enzootic circulation documented across all continents where small ruminant husbandry is practiced [3, 15, 35]. The virus is endemic in Asia, Africa, Europe, the Americas, and Oceania, causing significant economic losses in livestock production systems [3, 15]. While ORFV is classically considered a pathogen of sheep and goats, its host range extends far beyond these primary reservoirs, encompassing a diverse array of wild and domestic ruminants. The World Organisation for Animal Health (WOAH) recognizes ORFV as a significant transboundary pathogen, though it is not currently a notifiable disease, a status that contributes to its underreporting and neglect in many regions [15, 21].

The host spectrum of ORFV has expanded considerably through molecular epidemiological investigations. Beyond domestic sheep (Ovis aries) and goats (Capra hircus), natural infections have been confirmed in cattle, where outbreaks in Turkey demonstrated 100% nucleotide identity with caprine ORFV isolates, indicating a species barrier jump from goats to cattle [13]. This cross-species transmission is particularly concerning, as it suggests that ORFV can adapt to new hosts with relative ease. In wildlife, ORFV has been documented in Alaskan mountain goats (Oreamnos americanus), Dall’s sheep (Ovis dalli dalli), muskoxen (Ovibos moschatus), caribou (Rangifer tarandus granti), and Sitka black-tailed deer (Odocoileus hemionus sitkensis) [17]. The clinical severity in these wildlife species varies considerably; mountain goats exhibited the most severe proliferative lesions affecting multiple mucocutaneous regions, while caribou presented with ulcerative lesions on the lips and distal extremities [17]. In Japan, ORFV infection is continuously prevalent in wild Japanese serows (Capricornis crispus), goat-like bovids inhabiting mountainous regions [23]. Additionally, ORFV has been detected in chamois (Rupicapra rupicapra) in the Alpine regions of Austria, where phylogenetic analysis revealed high homology with domestic sheep ORFV strains, suggesting spillover from livestock sharing high-altitude summer pastures [27]. This wildlife-livestock interface represents a critical epidemiological nexus, as infected wildlife can serve as maintenance hosts, complicating eradication efforts in domestic populations.

Prevalence and Risk Factors in Livestock Populations

The seroprevalence and molecular detection rates of ORFV in livestock vary widely depending on geographical region, management practices, and diagnostic methodologies employed. In a comprehensive study in Terengganu, Malaysia, an overall seroprevalence of 22.8% was reported among 504 small ruminants, with goats showing a higher seropositivity rate (25.1%) compared to sheep (16.8%) [14]. This study identified species, age, and sex as significant risk factors (P < 0.05), with kids and female animals exhibiting higher prevalence [14]. The compliance level with herd health programs was alarmingly low (42.7%), with milking management recording the least compliance (-82.69%), directly correlating with sporadic disease outbreaks [14].

In Ethiopia, a country where ORFV is endemic but underreported, PCR-based screening of 400 randomly selected sheep and goats revealed an overall incidence of 12% [20]. Univariate logistic regression analysis identified several significant risk factors: sheep were more likely to be infected than goats; non-vaccinated and non-treated animals showed higher prevalence; nursing animals and those with poor body condition were at elevated risk; extensively managed animals had higher infection rates; and animals with visible mouth lesions were strongly associated with ORFV positivity [20]. Importantly, age and sex were not significant predictors in this Ethiopian study, contrasting with the Malaysian findings, suggesting that local epidemiological dynamics and husbandry practices modulate risk factor profiles [14, 20].

The morbidity rate of ORFV in naive flocks can approach 100%, with mortality rates typically low in adult animals but potentially reaching 10-20% in young lambs and kids due to starvation, secondary bacterial infections, and myiasis [15]. The malignant form of ORFV, characterized by persistent, proliferative lesions that fail to regress, can cause severe outbreaks with high mortality, particularly in newly infected young stock [15]. The economic impact is substantial, encompassing reduced weight gain, decreased milk production, increased culling rates, and the costs associated with treatment and biosecurity measures [2, 15].

Molecular Epidemiology and Phylogenetic Diversity

The genetic heterogeneity of ORFV isolates is a hallmark of its epidemiology, with significant implications for vaccine efficacy and cross-protection. Phylogenetic analyses based on the major envelope protein gene (B2L/ORFV011) and the F1L gene (ORFV059) have consistently demonstrated that ORFV strains cluster according to host species and geographical origin [16, 25, 30]. A seminal genomic study of four Fujian goat ORFV strains from southern China revealed that sheep-origin and goat-origin ORFVs form distinctly separate phylogenetic branches with 100% bootstrap support [25]. Furthermore, analysis of 132 individual genes across the ORFV genome identified 47 genes that can reliably distinguish between sheep and goat isolates, with gene 008 containing 33 unique amino acid residues that differentiate the two host lineages [25].

This host-specific clustering is not absolute, as evidenced by the transmission of caprine ORFV to cattle in Turkey [13] and the detection of sheep-like ORFV sequences in Alaskan Dall’s sheep [17]. However, the overall pattern suggests that ORFV strains undergo host adaptation, potentially limiting cross-species transmission efficiency. Within China, phylogenetic analysis of 13 ORFV strains collected between 2009 and 2011 identified three distinct genotypes based on B2L gene sequences, with amino acid substitutions dispersed among wild and attenuated vaccine strains [30]. Similarly, Ethiopian ORFV isolates from five geographical locations formed two main clusters, indicating the circulation of multiple genetic lineages within a single country [21].

The genetic diversity of ORFV is further compounded by the presence of microsatellites or simple sequence repeats (SSRs) throughout the genome. A comprehensive in-silico analysis of 11 ORFV strains identified 1,036–1,181 microsatellites per strain, with dinucleotide repeats being the most abundant (76.9%), followed by trinucleotide (17.7%) and mononucleotide (4.9%) repeats [8]. The relative abundance and density of these SSRs correlated significantly with GC content, and 13 polymorphic SSR markers were developed for strain identification and evolutionary studies [8]. This microsatellite diversity may contribute to the high heterogeneity observed among ORFV isolates, even within geographically restricted areas. In Fujian Province, China, isolates from 10 farms within a 120-kilometer radius showed remarkable heterogeneity, with only two isolates from farms within 1 km of each other sharing identical viral genes [37]. This finding underscores the existence of diverse ORFV populations in the environment, which may explain the phenomenon of recurring outbreaks despite prior exposure or vaccination.

Zoonotic Transmission and Human Infection Dynamics

ORFV is a well-documented zoonotic pathogen, causing a self-limiting but clinically significant disease in humans known as ecthyma contagiosum, or orf [4, 10, 11]. The World Health Organization (WHO) recognizes ORFV as an occupational hazard for individuals in contact with infected animals, though the true incidence of human orf is likely underestimated due to its self-limiting nature and the lack of mandatory reporting [4, 29]. The primary route of transmission is direct inoculation of the virus through broken skin following contact with infected animals or contaminated fomites, including scabs, crusts, and contaminated equipment [2, 4, 10].

Human infections typically manifest as solitary, 1-cm pustular lesions on the hands, fingers, or forearms, progressing through macular, papular, vesicular, and crusting stages over 4-6 weeks [4, 10]. However, atypical presentations can occur, including erythema multiforme, a hypersensitivity reaction that complicates approximately 5-10% of human orf cases, characterized by target-like skin eruptions distant from the primary lesion [26]. The immunological basis of this complication remains poorly understood, but it likely involves a delayed-type hypersensitivity response to viral antigens [26]. In rare instances, ORFV infection can be severe, as demonstrated by a thermal-burn patient who developed lesions at both the skin-graft harvest site and the recipient burn site, highlighting the risk of viral dissemination in immunocompromised or wounded patients [22].

The zoonotic risk is not confined to occupational exposure. Cultural and religious practices involving animal slaughter significantly contribute to human infections. Multiple case reports document ORFV transmission during Eid al-Adha, the Muslim Feast of Sacrifice, where families slaughter sheep or goats in their homes or in community settings [10, 11, 29]. In France, five cases of human orf were confirmed following Eid al-Adha, with infections occurring through skin wounds exposed to infected sheep tissues [29]. Similarly, a 45-year-old Moroccan-born man developed multiple painful plaques on his hands after butchering a sheep for Eid al-Adha [10]. A 65-year-old woman in France acquired ORFV after contact with a sheep during the Aïd-el-Fitr festival [11]. These cases underscore the importance of obtaining a thorough social and cultural history when evaluating patients with suspicious skin lesions, as the diagnosis may be missed in urban settings where occupational risk is absent [4, 10].

Novel Transmission Routes: Asymptomatic Shedding and Vector-Borne Potential

Traditional dogma held that ORFV transmission occurs exclusively through direct contact with infected animals exhibiting clinical lesions, particularly scabs and crusts that contain high viral loads. However, recent research has fundamentally challenged this paradigm by demonstrating that asymptomatic animals can shed infectious ORFV, potentially serving as unrecognized reservoirs for transmission.

A landmark study by Ma et al. (2022) detected infectious ORFV in the saliva and milk of dairy goats without any clinical signs of orf [2]. These isolates induced characteristic cytopathic changes in primary mammary and lip cells and, critically, produced typical orf lesions when inoculated into ORFV-free goats [2]. This finding has profound epidemiological implications, as it suggests that subclinically infected animals can contaminate feeding equipment, milking apparatus, and the environment, facilitating silent spread within herds. The presence of ORFV in milk also raises questions about the potential for lactogenic transmission to nursing offspring, a route that may contribute to the high morbidity observed in kids and lambs [2].

Similarly, Cheng et al. (2018) detected ORFV DNA in the blood of 628 asymptomatic goats across China, and the blood-derived virus was infectious, inducing typical contagious pustular dermatitis upon experimental inoculation [19]. This viremic phase in asymptomatic carriers indicates that ORFV can establish systemic infection without overt clinical signs, and blood-borne transmission via biting insects or contaminated needles cannot be discounted.

Perhaps the most intriguing novel transmission route involves the common housefly, Musca domestica. Raele et al. (2021) experimentally demonstrated that houseflies exposed to ORFV-contaminated scab homogenates could pick up and transmit viral DNA to contact surfaces, with 100% of flies testing positive for ORFV DNA on contact surfaces and 60% showing viral DNA in their crops and excreta (vomit and feces) [6]. While this study detected viral DNA rather than infectious virus, the ability of flies to mechanically transport ORFV to feeding sites, wounds, and mucous membranes represents a plausible mechanism for rapid within-herd spread, particularly in intensive management systems where fly populations are high [6]. The Centers for Disease Control and Prevention (CDC) has long recognized the potential for mechanical transmission of poxviruses by arthropods, and these findings align with that broader understanding.

Environmental Stability and Persistence

The epidemiological success of ORFV is partly attributable to its remarkable environmental stability, which facilitates indirect transmission through contaminated fomites and environments. Forced degradation studies by Eilts et al. (2023) demonstrated that ORFV infectivity remains robust within a pH range of 5.0–7.4, and ionic strength up to 0.5 M NaCl or MgCl₂ had no detrimental effect [1]. Short-term thermal stress of up to 37°C for two days did not reduce infectivity, and the virus withstood 20 repeated freeze-thaw cycles without significant loss of viability [1]. The virus exhibited low shear sensitivity to peristaltic pumps and mixing, though it was sensitive to ultrasonication [1]. The isoelectric point of ORFV genotype D1701-V was determined at pH 3.5, indicating that the virus carries a net negative charge at physiological pH, which influences its adsorption to surfaces and potential for aerosolization [1, 7].

These stability characteristics explain why ORFV can persist for months in dried scabs and crusts in the environment, on fences, feeding troughs, and bedding materials. The virus’s resistance to freeze-thaw cycles is particularly relevant in temperate climates where winter conditions may not effectively inactivate environmental contamination. This environmental persistence, combined with the identification of asymptomatic shedders and potential insect vectors, creates a complex epidemiological landscape where traditional biosecurity measures may be insufficient to prevent introduction and spread.

Implications for Control and Public Health

The expanding understanding of ORFV epidemiology has direct implications for disease control strategies. The recognition that asymptomatic animals can shed virus in saliva, milk, and blood necessitates a reevaluation of quarantine protocols and pre-movement testing [2, 19]. Current vaccination strategies, primarily employing live-attenuated vaccines, provide partial protection but are associated with safety concerns, including the potential for reversion to virulence and the induction of only short-term immunity [3, 15]. The genetic heterogeneity of circulating ORFV strains, as demonstrated by the existence of multiple genotypes within single countries and even within small geographical areas, suggests that vaccine strains may not provide adequate cross-protection against all field isolates [25, 30, 37].

From a public health perspective, the CDC and WHO emphasize the importance of educating at-risk populations, including farmers, veterinarians, slaughterhouse workers, and individuals participating in religious animal sacrifice, about the zoonotic risks of ORFV [4, 10, 29]. The use of personal protective equipment, including gloves, during handling of animals or animal products, and prompt wound care following potential exposures, are critical preventive measures. The underdiagnosis of human orf, particularly in urban settings where clinicians may not consider occupational or cultural exposures, highlights the need for increased awareness among healthcare providers [4, 26].

The detection of ORFV in wildlife populations across Alaska, Austria, and Japan further complicates control efforts, as wildlife can serve as reservoirs for reintroduction into livestock populations [17, 23, 27]. The Food and Agriculture Organization (FAO) has called for integrated surveillance programs that monitor ORFV circulation at the livestock-wildlife interface, particularly in regions where transhumance or shared grazing practices bring domestic and wild animals into contact.

Clinical Manifestations and Pathology in Host Species

Orf virus (ORFV), the prototype species of the genus Parapoxvirus within the family Poxviridae, induces a disease spectrum that ranges from subclinical carriage to severe, proliferative, and occasionally fatal dermatopathy across a remarkably broad range of mammalian hosts [3, 15, 18]. The clinical manifestations and underlying pathology are profoundly influenced by host species, age, immune status, viral strain virulence determinants, and the anatomical site of infection. While the disease is classically described as a self-limiting, benign condition in immunocompetent small ruminants, the reality is far more nuanced, encompassing persistent infections, malignant transformations, severe secondary complications, and significant zoonotic potential that demands attention from veterinary and public health authorities alike, including the World Organisation for Animal Health (WOAH) and the World Health Organization (WHO), given its global distribution and economic impact.

Clinical Manifestations in Primary Hosts: Sheep and Goats

In sheep and goats, the primary natural reservoirs, ORFV infection manifests as contagious ecthyma, also known as contagious pustular dermatitis or "soremouth" [3, 15]. The disease is characterized by a predictable progression through papular, vesicular, pustular, and scabby stages, typically localized to the mucocutaneous junctions of the lips, nares, oral commissures, and perioral region [5, 15, 20]. The initial lesions, appearing 3–7 days post-infection, are erythematous macules that rapidly evolve into papules and then vesicles. These vesicles are often transient and easily ruptured, progressing to pustules that subsequently form thick, brownish, friable crusts or scabs [5, 15]. The proliferative nature of the lesions is a hallmark, often resulting in exophytic, papillomatous-like masses that can become quite large, particularly in young animals [15, 17]. Lesion severity and distribution can be classified into three primary forms: labial, genital, and mammary, with a generalized form also recognized in severe cases [15].

The labial form is the most common, affecting the lips, muzzle, and oral cavity. In lambs and kids, this can lead to significant morbidity due to pain and mechanical obstruction, preventing effective suckling and leading to malnutrition, weight loss, and increased susceptibility to secondary infections [15, 20]. The genital form presents as pustular and scabby lesions on the vulva, prepuce, and scrotum, which can lead to balanoposthitis, vulvovaginitis, and temporary infertility [15, 38]. The mammary form involves the teats and udder skin, causing pain during milking, predisposing the animal to mastitis, and creating a potential source of infection for suckling offspring and, critically, for human handlers during milking [2, 15]. A particularly severe, malignant form of orf has been described, characterized by persistent, non-healing, proliferative lesions that can extend into deeper tissues, become infected with bacteria, and ultimately prove fatal, especially in immunocompromised or young animals [15].

The duration of clinical disease is typically 4–6 weeks, with scabs sloughing off and underlying tissue healing, often without scarring [15]. However, the virus can persist in scabs for extended periods in the environment, contributing to its high contagiousness [6]. A critical feature of ORFV pathogenesis is its ability to repeatedly infect previously exposed or vaccinated animals [3, 15, 18]. This is not due to a lack of immune response but rather to the virus's sophisticated arsenal of immunomodulatory genes that temporarily subvert host immunity, allowing for reinfection cycles that are essential for viral maintenance in populations [3, 5, 24].

Subclinical Carriage and Atypical Transmission Routes

A paradigm-shifting finding in recent years is the detection of infectious ORFV in the saliva and milk of clinically asymptomatic dairy goats [2]. This discovery challenges the traditional dogma that transmission occurs solely through direct contact with active lesions or contaminated fomites. The isolated viruses were shown to be fully infectious, capable of inducing characteristic cytopathic effects in primary mammary and lip cells and, critically, producing typical orf lesions upon experimental inoculation of naïve goats [2]. This subclinical shedding has profound implications for disease control, as apparently healthy animals can serve as silent reservoirs, perpetuating viral circulation within a herd and potentially contaminating milk supplies. Similarly, ORFV DNA has been detected in the blood of asymptomatic goats, further supporting the concept of a carrier state [19]. The viremic phase, while likely transient, may facilitate systemic dissemination and contribute to the establishment of infection at distant mucocutaneous sites [19]. These findings underscore the inadequacy of relying solely on clinical inspection for surveillance and highlight the need for molecular diagnostic tools, such as those recommended by the WOAH, to identify subclinical carriers.

Pathology and Virulence Determinants

The pathological hallmark of ORFV infection is profound epidermal hyperplasia (acanthosis) and parakeratotic hyperkeratosis, resulting in the characteristic scabby, proliferative lesions [17, 24]. The virus is highly epitheliotropic, replicating primarily in regenerating keratinocytes of the stratum spinosum [24]. This tropism is facilitated by viral factors such as a homologue of anaphase-promoting complex subunit, which manipulates the host cell cycle to enhance viral DNA synthesis specifically in these cells [24]. The intense proliferation is driven, in part, by a viral vascular endothelial growth factor (VEGF-E) homologue, which is a potent angiogenic factor that induces profound vascular proliferation and increased vascular permeability, contributing to the exudative and proliferative nature of the lesions [24, 34]. The scabs themselves are composed of a mixture of degenerated keratinocytes, inflammatory cells, fibrin, and embedded virions, which are shed in vast quantities into the environment [6].

The severity of clinical disease is directly linked to the expression of specific viral immunomodulatory proteins (IMPs). Targeted deletion of genes encoding the chemokine binding protein (CBP; ORFV112), the inhibitor of granulocyte-monocyte colony-stimulating factor and IL-2 (GIF; ORFV117), and the viral interleukin-10 homologue (vIL-10; ORFV127) from the virulent IA82 strain resulted in a measurable, albeit partial, attenuation of virulence in lambs [5]. While the onset and peak severity of lesions were similar between the deletion mutants and the parental virus, the resolution phase was significantly accelerated in lambs infected with the deletion mutants. Lesions regressed faster, and viral shedding from lesions ceased earlier, indicating that these IMPs are critical for prolonging infection and delaying viral clearance [5]. This highlights the delicate balance ORFV strikes: it must induce sufficient inflammation to create a permissive environment for replication while simultaneously dampening key antiviral pathways to avoid rapid elimination [3, 24]. The virus also employs a unique strategy to evade CD8+ T-cell recognition by disrupting the intracellular transport of MHC class I molecules. ORFV infection causes structural fragmentation of the Golgi apparatus, leading to a reduction in MHC I surface expression of up to 50%, thereby impairing the presentation of viral antigens to cytotoxic T lymphocytes [33].

Host Range and Species-Specific Manifestations

While sheep and goats are the primary hosts, ORFV demonstrates a remarkable ability to cross species barriers, causing disease in a wide range of domestic and wild ruminants, as well as other mammals [13, 17, 27]. In cattle, ORFV infection has been confirmed as the cause of proliferative skin lesions, with outbreaks reported in Turkey where the virus was shown to have jumped the species barrier from goats [13]. The lesions in cattle were clinically indistinguishable from other poxviral infections, such as pseudo-lumpy skin disease (caused by bovine herpesvirus 2), underscoring the need for molecular confirmation [13].

Wildlife species are also susceptible and may serve as important reservoirs. A comprehensive investigation in Alaskan wildlife documented ORFV infection in mountain goats (Oreamnos americanus), Dall's sheep (Ovis dalli dalli), muskoxen (Ovibos moschatus), caribou (Rangifer tarandus granti), and Sitka black-tailed deer (Odocoileus hemionus sitkensis) [17]. Clinical signs were most severe in mountain goats, with extensive proliferative masses affecting multiple mucocutaneous regions, including the palpebrae, nares, lips, anus, and coronary bands [17]. Dall's sheep showed similar but less extensive lesions, while muskoxen presented with ulcerative lesions on the legs. The caribou exhibited ulcerative lesions on the lip and distal limbs [17]. This study was the first to report ORFV infection in caribou and Sitka black-tailed deer, highlighting the expanding host range and the potential for wildlife-livestock-human interfaces to facilitate viral spread [17]. Similarly, ORFV infection has been documented in Japanese serows (Capricornis crispus) and chamois (Rupicapra rupicapra), with evidence suggesting transmission from domestic sheep sharing alpine pastures [23, 27]. The genetic diversity among ORFV strains, as revealed by phylogenetic analyses of the B2L and F1L genes, often correlates with host species and geographic origin, with goat and sheep isolates frequently forming distinct clusters [25, 32]. This host-specific adaptation is reflected in the presence of unique amino acid signatures in certain viral genes, such as gene 008, which can distinguish between sheep and goat-derived strains [25].

Clinical Manifestations in Humans: Zoonotic Infection

Human orf is an occupational and cultural zoonosis, typically acquired through direct contact with infected animals or contaminated fomites, including carcasses [4, 10, 11, 29]. Individuals at highest risk include farmers, veterinarians, slaughterhouse workers, and those participating in religious or cultural practices involving animal sacrifice, such as Eid al-Adha [4, 10, 29]. The incubation period is 3–7 days. The classic lesion is a solitary, painful, erythematous to violaceous nodule or pustule, typically 1–2 cm in diameter, most commonly located on the fingers, hands, or forearms, the sites of inoculation [4, 10, 11]. The lesion progresses through the same stages as in animals: macule, papule, vesicle, pustule, and finally a thick, crusted scab, which typically resolves spontaneously over 4–8 weeks, often without scarring [4, 10]. However, multiple lesions can occur, and the clinical presentation can be highly variable, sometimes mimicking other infections such as anthrax, cowpox, or milker's nodule, making a thorough exposure history essential for diagnosis [4].

A significant complication of human orf is the development of erythema multiforme (EM), an acute, immune-mediated hypersensitivity reaction [26]. EM typically appears 1–3 weeks after the onset of the primary orf lesion and presents as target-like macules, papules, and vesicles, often symmetrically distributed on the extremities, including the palms and soles [26]. The pathogenesis is thought to involve a T-cell-mediated immune response directed against viral antigens, leading to keratinocyte apoptosis [26]. While EM is usually self-limiting, it can be extensive and painful, and its occurrence can be a diagnostic clue for an underlying orf infection [26]. A particularly unusual case involved a burn patient who developed ORFV lesions at both the skin graft harvest site and the recipient burn site, demonstrating the virus's ability to infect compromised skin and the potential for iatrogenic spread [22]. The diagnosis of human orf is confirmed by PCR, electron microscopy, or histopathology, and management is primarily supportive, as the disease is self-limiting [4, 11]. Prevention relies on education, use of personal protective equipment (gloves) when handling animals or animal products, and public health awareness, particularly in communities where animal slaughter is a cultural practice [4, 29].

Diagnostics and Detection of Orf Virus

The accurate and timely diagnosis of Orf virus (ORFV) infection is paramount for effective disease management, prevention of zoonotic transmission, and implementation of control measures in both domestic livestock and wildlife populations. As the causative agent of contagious ecthyma, a disease recognized by the World Organisation for Animal Health (WOAH) as a significant economic burden in small ruminant industries, and a zoonotic pathogen capable of infecting humans through direct contact with infected animals or fomites, the diagnostic landscape for ORFV must balance speed, sensitivity, specificity, and field applicability. The diagnostic armamentarium for ORFV has expanded considerably over the past decade, driven by advances in molecular biology, isothermal amplification technologies, and genomic characterization. These tools are essential not only for confirming clinical cases but also for epidemiological surveillance, phylogenetic tracking, and understanding the virus’s ability to persist in asymptomatic carriers and novel host species.

Traditional and Histopathological Diagnostics

Clinical diagnosis of ORFV infection in sheep and goats is often presumptive, based on the characteristic proliferative, pustular, and scabby lesions localized to the lips, oral commissures, nostrils, udders, and coronary bands. In human cases, a solitary, 1-cm pustular lesion on the hand, often accompanied by a history of contact with small ruminants, is considered pathognomonic by experienced dermatologists [4, 10, 26]. However, the clinical presentation can be confounded by similar lesions caused by other poxviruses, bacterial infections, or autoimmune conditions, necessitating laboratory confirmation. Histopathological examination of biopsy specimens reveals hallmark features including acanthosis, ballooning degeneration of keratinocytes, intracytoplasmic eosinophilic inclusion bodies, and dermal edema with a mixed inflammatory infiltrate [4, 22]. These findings, while supportive, are not definitive, as other parapoxviruses produce identical cytopathic changes. Moreover, histology cannot differentiate ORFV from pseudocowpox virus or bovine papular stomatitis virus, which share morphological characteristics and zoonotic potential [4]. Despite its limitations, histopathology remains a valuable adjunct, particularly in atypical presentations such as the first reported case of ORFV infection in a skin graft harvest site in a burn patient, where inclusion bodies and ballooning degeneration were observed [22].

Electron Microscopy

Direct visualization of virions by electron microscopy (EM) has historically been a gold standard for parapoxvirus identification. ORFV particles exhibit a distinctive ovoid shape with a crisscross pattern of tubular surface filaments, measuring approximately 260 × 160 nm [16, 27, 29]. Negative staining of vesicular fluid or scab homogenates provides rapid, species-level identification within hours, and EM has been instrumental in confirming human infections acquired during religious practices such as Eid al-Adha [29] and in hunters handling game [27]. However, EM requires specialized equipment and skilled personnel, limiting its use to reference laboratories. Additionally, EM cannot differentiate between ORFV and other parapoxviruses that share identical morphology, such as the virus causing pseudocowpox or bovine papular stomatitis [29]. Consequently, EM is now primarily used as a confirmatory tool in combination with molecular assays, particularly when novel or unexpected hosts are involved, as in the case of ORFV infection in caribou and Sitka black-tailed deer in Alaska [17].

Viral Isolation and Cell Culture

The isolation of infectious ORFV in cell culture remains a definitive diagnostic method and is essential for downstream applications such as vaccine development, virulence studies, and genomic sequencing. ORFV can be propagated in a variety of primary and continuous cell lines, including ovine, caprine, and bovine primary cells, as well as Vero cells, which are widely used due to their permissiveness and availability [11, 16, 20, 32]. After inoculation, characteristic cytopathic effects (CPE), including cell rounding, detachment, and syncytium formation, typically appear within 48 to 72 hours, though primary isolation from field samples may require multiple passages. For example, the isolation of the NA1/11 strain from a sheep outbreak in China was achieved in Vero cells, and the purified virions were subsequently confirmed by atomic force microscopy [32]. Similarly, isolation of ORFV from human nodules using a nonconventional cell line enabled genome sequencing of a novel French strain [11]. Isolation not only confirms viability but also facilitates phenotypic characterization, such as the assessment of virulence gene deletions in recombinants [5, 25]. However, viral isolation is time-consuming, requires biosafety level 2 facilities, and may fail if samples are degraded or contain non-viable virus. Moreover, the presence of infectious virus in atypical samples, such as the isolation of ORFV from the saliva and milk of asymptomatic goats [2] and from the blood of clinically normal animals [19], underscores the importance of culture for understanding transmission dynamics, as these cell culture-derived isolates induced typical lesions upon inoculation into naïve goats [2, 19].

Molecular Diagnostics: PCR and Real-Time PCR

Polymerase chain reaction (PCR) has become the cornerstone of ORFV diagnostics due to its high sensitivity, specificity, and rapid turnaround time. Conventional PCR assays targeting conserved genes such as the major envelope protein gene (B2L; ORFV011) and the F1L gene (ORFV059) are widely employed for detection and phylogenetic analysis [13, 16, 17, 20, 21, 27, 30, 32, 38, 44]. These assays can amplify ORFV DNA from scabs, vesicular fluid, saliva, milk, blood, and even environmental samples such as fly-contaminated surfaces [2, 6, 19]. The B2L gene, encoding a homolog of vaccinia virus F13L, is particularly well-conserved across parapoxviruses and allows for genus-level confirmation, while subsequent sequencing enables species differentiation and strain typing [21, 30, 38]. For instance, a PCR-based survey of asymptomatic goats in China detected ORFV DNA in 628 blood samples, revealing a previously unrecognized carrier state [19]. Similarly, PCR analysis of scabs and crop contents from houseflies (Musca domestica) demonstrated the potential role of mechanical vectors in ORFV transmission, with 60% of flies testing positive for viral DNA [6].

Real-time PCR assays offer enhanced sensitivity and quantification capabilities compared to conventional PCR. A SYBR Green I-based real-time PCR targeting the B2L gene achieved a detection limit of 20 copies of ORFV genomic DNA per reaction, with no cross-reactivity against other common DNA viruses [42]. This assay reduced the time-to-result to approximately 1.5 hours and demonstrated superior sensitivity and speed relative to conventional PCR when testing clinical samples from sheep and goats in China [42]. Quantitative real-time PCR is particularly valuable for monitoring viral shedding kinetics in experimental infections, as demonstrated in a study where lambs inoculated with recombinant ORFV lacking immunomodulatory genes (CBP, GIF, vIL-10) showed significantly reduced viral shedding from days 16–21 post-inoculation compared to the parental virus [5]. The ability to quantify viral load is also critical for assessing the efficacy of disinfectants, stability studies during vaccine production [1], and downstream purification processes [39]. However, real-time PCR requires expensive equipment and trained personnel, limiting its utility in resource-limited settings.

Isothermal Amplification Assays: RAA, RPA, and LAMP

The need for rapid, field-deployable diagnostics has driven the development of isothermal amplification technologies that circumvent the requirement for thermal cyclers. Recombinase-aided amplification (RAA) operates at a constant temperature (typically 37–42°C) and can amplify target DNA within 20 minutes. An RAA assay for ORFV, targeting the B2L gene, exhibited an analytical sensitivity of 1 × 10¹ copies per reaction, with no cross-reactivity with capripoxvirus, foot-and-mouth disease virus, or peste des petits ruminants virus [40]. When evaluated against 45 archived nasal scab samples, the RAA assay demonstrated excellent agreement (kappa = 0.845) with SYBR Green real-time PCR, confirming its suitability for clinical diagnostics [40].

Recombinase polymerase amplification (RPA) has been adapted for ORFV detection in two formats: a fluorescent probe-based exo RPA assay and a lateral flow dipstick (LFD) assay. The exo RPA assay, which uses a real-time fluorescence reader, can detect as few as 100 copies of ORFV DNA per reaction within 20 minutes and showed 100% specificity when tested against related viruses [46]. The RPA-LFD assay combines amplification with immunochromatographic detection on a strip, enabling visual readout without specialized instrumentation. This assay achieved a detection limit of 80 copies per reaction and completed the entire process in under 25 minutes, making it an ideal “point of care” tool for field surveillance [43]. Both RPA formats correlated well with qPCR when applied to clinical samples from goats and sheep in China, demonstrating their robustness for onsite diagnosis [43, 46].

Loop-mediated isothermal amplification (LAMP) represents another isothermal alternative that has been optimized for ORFV detection in wild ruminants. A LAMP assay using Bst or Csa DNA polymerases, combined with the colorimetric indicator hydroxynaphthol blue (HNB), enabled visual diagnosis by the naked eye within 60 minutes [23]. This assay was successfully adapted for on-site use in Japanese serows (Capricornis crispus), a wild goat-like species where ORFV infection is enzootic. DNA was extracted from oral lesions using a commercial kit without electricity, and amplification was performed in a portable cordless incubator, demonstrating that definitive diagnosis can be achieved in remote mountainous areas [23]. The LAMP assay amplified DNA from all tested ORFV strains, confirming its broad reactivity, though quantitative performance is not possible with this format.

Serological Diagnostics

Serological detection of ORFV-specific antibodies provides evidence of past exposure or vaccination and is valuable for epidemiological surveys and herd-level surveillance. Enzyme-linked immunosorbent assays (ELISAs) and virus neutralization tests (VNTs) have been employed, though they are less commonly used for acute diagnosis due to the transient nature of the antibody response and the virus’s immunomodulatory properties. The B2L protein, in addition to its structural role, has been identified as a potent immunomodulator that induces immune cell accumulation at inoculation sites and serves as an adjuvant [31]. Recombinant B2L-based ELISA has been shown to detect antibodies in experimentally infected animals, and the B2L gene is often used in DNA vaccine constructs to enhance immunogenicity [41]. In a seroprevalence study of 504 small ruminants in Malaysia, 22.8% of animals tested positive for ORFV antibodies by an indirect ELISA, with risk factors including species (goats > sheep), age (kids/lambs > adults), and clinical lesion presence [14]. Serological surveys in Alaska detected ORFV antibodies in chamois, suggesting spillover from domestic sheep to wildlife [27]. However, serology cannot differentiate between infected and vaccinated animals, and the virus’s ability to repeatedly infect hosts due to immunomodulatory genes [3, 24] complicates interpretation of antibody titers. Moreover, the availability of standardized, commercial serological assays for ORFV is limited, and most studies rely on in-house ELISAs or VNTs.

Genomic Characterization and Phylogenetic Analysis

The advent of affordable next-generation sequencing has revolutionized ORFV diagnostics by enabling whole-genome sequencing and detailed phylogenetic analysis. Genome-wide comparisons have revealed significant heterogeneity among ORFV isolates, particularly in the terminal regions where immunomodulatory and virulence genes are located [12, 24, 25]. For instance, sequencing of four goat ORFV strains from Fujian Province, China, identified gene deletions (e.g., loss of seven genes in the OV-NP strain and three genes in OV-SJ1) that correlated with reduced virulence in goats, highlighting the utility of genomic characterization for predicting pathogenicity [25]. Microsatellite or simple sequence repeat (SSR) analysis has also been developed as a tool for genetic diversity assessment; 13 polymorphic SSR markers were identified from 11 ORFV strains and validated by PCR and sequencing, offering a high-resolution method for strain discrimination and evolutionary studies [8].

Phylogenetic analysis based on the B2L and F1L genes is routinely used to classify ORFV isolates and trace transmission routes. Studies have demonstrated that ORFV sequences from goats and sheep often form distinct clusters, and cross-species transmission can be identified when isolates from different hosts share high sequence identity [13, 25, 32]. For example, B2L gene sequences from Turkish cattle isolates were 100% identical to goat isolates from the same region, providing molecular evidence of a host species barrier jump [13]. Similarly, phylogenetic analysis of the GIF and vIL-10 genes from Alaskan wildlife revealed that Dall’s sheep sequences clustered with domestic sheep ORFV, whereas sequences from mountain goats, muskoxen, and caribou formed a separate group, suggesting divergent evolutionary trajectories [17]. In humans, genomic sequencing of a French isolate from a 65-year-old woman who handled a sheep during Eid al-Fitr identified a novel ORFV genome, underscoring the role of cultural practices in transmission and the need for global genomic surveillance [11].

The use of phylogenetic analysis also aids in distinguishing ORFV from other parapoxviruses. In a Tanzanian study, PCR and sequencing of the GIF/IL-2 gene confirmed ORFV as the cause of proliferative dermatitis in goats, providing the first molecular characterization of the virus in that country [45]. Such data are critical for implementing control measures and understanding the global distribution of ORFV genotypes, particularly in regions where the disease is underreported, such as Ethiopia, where two main clusters were identified based on A32L and B2L genes [21].

Detection in Atypical Samples and Asymptomatic Carriers

Emerging evidence indicates that ORFV can be detected in samples from animals without overt clinical signs, challenging the traditional paradigm that transmission occurs only via direct contact with lesions. The detection of infectious ORFV in the saliva and milk of asymptomatic dairy goats by PCR and cell culture was a landmark finding, as these secretions represent novel transmission routes with implications for biosecurity [2]. Inoculation of these isolates into ORFV-free goats produced typical lesions, confirming that carriers can shed viable virus [2]. Similarly, ORFV DNA was detected in the blood of 628 asymptomatic goats across China, and blood-derived isolates induced contagious pustular dermatitis upon experimental infection [19]. These findings suggest that hematogenous dissemination may occur during subclinical infection, and blood sampling could serve as a non-invasive diagnostic strategy for surveillance.

Environmental sampling has also gained attention, particularly regarding the role of mechanical vectors. Houseflies experimentally exposed to ORFV-contaminated scabs were able to transfer viral DNA to contact surfaces and were themselves positive in 60% of crop and spot samples, as detected by PCR [6]. This highlights the potential for ORFV to persist in the environment and be disseminated by insects, necessitating integrated pest management in control programs.

Conclusion-Less Remarks on Diagnostic Challenges

Despite the breadth of available diagnostic tools, several challenges remain. The high genetic diversity among ORFV strains [24, 30, 37] can lead to false negatives if primers or probes are designed against variable regions, necessithe constant updating of molecular targets. The virus’s immunomodulatory arsenal, including chemokine binding proteins, a GM-CSF/IL-2 inhibitor, vIL-10, and inhibitors of NF-κB signaling [3, 5, 24, 33], can suppress host immune responses and interfere with serological detection, particularly in early infection. Additionally, the stability of ORFV infectivity across a wide pH range (5–7.4), resistance to repeated freeze-thaw cycles, and low shear sensitivity [1] mean that samples may remain infectious during transport and processing, requiring appropriate biosafety precautions but also enabling robust diagnostic workflows. The integration of isothermal amplification assays with portable devices and colorimetric detection systems, as demonstrated with LAMP [23] and RPA-LFD [43], represents a promising path forward for rapid, on-site diagnosis in low-resource settings. As ORFV continues to emerge in new host species and geographic regions, from cattle in Turkey [13] to wildlife in Alaska [17] and humans through cultural practices [10, 11, 29], a comprehensive, multi-platform diagnostic approach will be essential for timely intervention and global surveillance.

Transmission Dynamics and Emerging Routes (Saliva and Milk)

The epidemiology of Orf virus (ORFV) has long been defined by a paradigm of direct contact transmission, primarily through the inoculation of virus-laden scabs, fomites, or contaminated feeding equipment into abrasions on the skin or oral mucosa of susceptible hosts. The canonical route involves the shedding of infectious virus from exudative, proliferative lesions that characterize contagious ecthyma. Scabs, which can remain viable in the environment for extended periods, are considered the primary reservoir of infectious material, facilitating both within-herd spread and inter-herd transmission via contaminated premises [6, 14, 15]. However, a growing body of evidence, driven by sophisticated molecular diagnostics and targeted field investigations, has fundamentally challenged this narrow view, revealing a far more complex transmission network that includes previously unrecognized, and potentially epidemiologically significant, routes. The most transformative of these discoveries is the detection and isolation of infectious ORFV from the saliva and milk of clinically asymptomatic animals, which has redefined our understanding of viral shedding and the potential for silent spread within livestock populations.

The seminal work by Ma et al. (2022) provided the first unequivocal evidence that ORFV can be shed in the saliva and milk of dairy goats in the absence of any visible clinical signs [2]. In this study, ORFV was detected via PCR and, critically, successfully isolated in cell culture from both saliva and milk samples collected from a commercial goat herd. The isolated viruses were not merely genetic remnants; they were demonstrated to be fully infectious. They induced characteristic cytopathic effects in primary mammary and lip cell cultures and, most importantly, produced typical orf lesions following experimental inoculation into ORFV-free goats [2]. This finding dismantles the long-held assumption that viral shedding is synonymous with the presence of active, observable lesions. The presence of infectious virus in the saliva of asymptomatic animals is particularly alarming from a transmission perspective. Saliva is a vehicle for direct oro-nasal contact, contamination of shared water sources, licking of pen mates or offspring, and deposition onto feeding equipment. The oral cavity, a primary site for ORFV entry, could be constantly exposed to a low-level inoculum from asymptomatic carriers, potentially leading to the establishment of infection in naive animals without the dramatic, acute outbreak that typically follows exposure to a heavily contaminated environment or a lesion-donor animal.

The implications for lactational transmission are equally profound. The detection of infectious ORFV in milk [2] introduces a novel vertical and horizontal transmission pathway. For neonatal kids and lambs, which are highly susceptible to severe, often fatal, orf infections, milk represents a direct and frequent route of exposure. Suckling from an asymptomatic dam could deliver a consistent dose of virus to the immature oral and gastrointestinal mucosa. This mechanism could explain the high morbidity and mortality rates often observed in very young animals, which are sometimes inexplicable in the context of a clean environment and the absence of obvious lesions on the mother. Furthermore, from a public health and food safety standpoint, the presence of infectious ORFV in milk from asymptomatic goats warrants attention. While ORFV is not currently classified as a major foodborne pathogen, its zoonotic potential is well-documented [4, 10, 11, 29]. The handling of raw milk or consumption of unpasteurized dairy products from asymptomatically infected animals could pose a risk to human health, particularly for individuals with compromised skin barriers (e.g., cuts on hands during milking) or mucosal exposure. This route adds a layer of complexity to the risk profile of ORFV, moving beyond direct contact with overtly diseased animals and carcasses during religious or occupational slaughter [10, 11, 29].

The biological mechanisms enabling this subclinical shedding are likely rooted in the virus's sophisticated immunomodulatory arsenal. ORFV encodes a suite of virulence factors that actively subvert the host immune response, including a viral interleukin-10 (vIL-10) homologue, a chemokine binding protein (CBP), and an inhibitor of GM-CSF and IL-2 (GIF) [5, 24]. These factors are not merely present; they are expressed early in infection and are crucial for dampening the host's inflammatory and antiviral responses. It is plausible that in some animals, a low-grade, focal infection of the salivary glands or mammary epithelium occurs, where the immunomodulatory proteins successfully limit inflammation and systemic pathology, allowing the virus to replicate and be shed without triggering the classic proliferative lesion. The virus's ability to downregulate MHC class I surface expression and disrupt Golgi-mediated vesicular transport further aids in immune evasion at the single-cell level, potentially facilitating a persistent, low-level replication state at mucosal surfaces [33]. The presence of ORFV in the blood of asymptomatic goats, as reported by Cheng et al. (2018), provides a hematogenous route for virus dissemination to the mammary gland or salivary tissues, seeding peripheral shedding sites [19]. This viremic phase in otherwise healthy animals underscores that ORFV infection can be systemic and not merely a localized skin disease.

This expanded understanding of transmission dynamics has immediate and critical implications for disease control and surveillance. Traditional control measures focus on quarantine of visibly affected animals, disinfection of contaminated environments, and vaccination of naive flocks. However, these strategies are rendered partially ineffective if a significant proportion of the herd consists of asymptomatic shedders. Standard quarantine periods based on the resolution of clinical lesions may be insufficient, as these animals may continue to silently excrete virus in their saliva and milk. This phenomenon could explain the frustratingly frequent recurrence of orf outbreaks in vaccinated herds, as new naive animals can be infected from asymptomatic carriers before the vaccine-induced immunity is fully established [3, 15]. The detection of ORFV in the milk of asymptomatic goats also necessitates a re-evaluation of biosecurity protocols on dairy farms, particularly regarding the separation of dams and offspring, milking hygiene, and the handling of milk products.

Furthermore, the discovery of these new routes contextualizes other unconventional modes of transmission. The mechanical transmission of ORFV by insects, such as the common house fly (Musca domestica), must now be considered in light of these findings. Raele et al. (2021) demonstrated that flies can pick up ORFV DNA from contaminated surfaces and deposit it on new surfaces [6]. While their study used scab homogenate, the presence of virus in the saliva and milk of animals provides a fresh, moist, and potentially more accessible substrate for insect vectors. Flies feeding on the saliva around an animal's mouth or on spilled milk could become contaminated and subsequently transmit the virus to uninfected animals, especially through the common practice of flies congregating around the eyes, nares, and mouths of livestock. The interaction between mechanical vectors and these newly identified shedding routes could amplify the speed and breadth of transmission within a herd, particularly during warmer months when fly populations are high.

In summary, the detection of infectious ORFV in the saliva and milk of asymptomatic goats represents a paradigm shift in the epidemiology of this economically significant zoonotic pathogen [2]. It moves the narrative from a simple, lesion-based transmission cycle to a far more complex model involving persistent, subclinical shedders and multiple concurrent shedding pathways. This discovery has profound implications for the design of effective control programs, the understanding of herd immunity, and the assessment of zoonotic risk, particularly in the dairy industry. It underscores the necessity for surveillance strategies that go beyond clinical inspection and incorporate molecular detection of the virus in bodily fluids to truly understand the prevalence and transmission dynamics of ORFV in both domestic and wild ruminant populations. The health of the global sheep and goat industry, as well as the safety of those who work with them, depends on integrating these emerging routes into our foundational understanding of how Orf virus moves through the world.

Stability, Inactivation, and Pharmaceutical Production of Orf Virus

The transition of Orf virus (ORFV) from a naturally occurring zoonotic pathogen to a sophisticated viral vector platform necessitates a rigorous, data-driven understanding of its physicochemical stability, inactivation kinetics, and the engineering principles governing its pharmaceutical manufacture. As a leading candidate for both prophylactic and therapeutic vaccine applications, including phase I clinical trials, the ORFV platform demands a production process that is not only scalable but also robust against environmental stressors that could compromise infectivity and, consequently, immunogenicity [1, 9, 12]. This section provides an exhaustive analysis of the critical parameters affecting ORFV stability, the mechanisms of its inactivation, and the state-of-the-art in its downstream processing and formulation, drawing exclusively on the available corpus of research.

Physicochemical Stability: Defining the Operational Envelope

The stability of ORFV infectivity is a function of its complex, enveloped architecture, which is inherently more labile than non-enveloped viruses. Systematic forced degradation studies have been instrumental in mapping the boundaries of this stability. The virus demonstrates a remarkable resilience within a defined pH range, maintaining full infectivity between pH 5.0 and 7.4 [1]. This tolerance is particularly advantageous for pharmaceutical processing, as it allows for the use of common, well-characterized buffering systems such as TRIS, HEPES, and phosphate-buffered saline (PBS) without significant loss of viral titer [1]. The isoelectric point (pI) of the ORFV genotype D1707-V has been determined to be approximately pH 3.5 [1, 7]. This acidic pI is a critical parameter for downstream purification strategies, particularly ion-exchange chromatography, as it dictates the net surface charge of the virion under varying pH conditions. The virus's stability above its pI, within the neutral range, aligns well with physiological conditions and standard cell culture media.

Ionic strength, a key variable in both upstream and downstream processing, exerts a selective effect on ORFV stability. The virus is notably tolerant to high concentrations of sodium chloride (NaCl) and magnesium chloride (MgCl₂), with no significant loss of infectivity observed at ionic strengths up to 0.5 M [1]. This tolerance is crucial for steps such as diafiltration, buffer exchange, and certain chromatographic elution conditions. However, a critical exception exists with ammonium chloride (NH₄Cl), which was found to destabilize the virus significantly [1]. This finding is mechanistically important, as NH₄Cl is a known lysosomotropic agent that raises the pH of acidic intracellular compartments. While its destabilizing effect on the extracellular virion may involve different mechanisms, potentially related to chaotropic effects on the viral envelope or disruption of surface protein conformation, it mandates the exclusion of ammonium-based buffers from any formulation or purification step involving ORFV.

Thermal and Mechanical Stress: Process Robustness and Vulnerability

Thermal stability is a cornerstone of pharmaceutical product shelf-life and cold-chain management. ORFV exhibits a surprising degree of thermotolerance for an enveloped virus. Short-term thermal stress at 37°C for up to two days does not diminish its infectivity [1]. This stability is a significant advantage for short-term handling during manufacturing and for potential use in regions with less robust cold-chain infrastructure. The resilience to repeated freeze-thaw cycles is equally notable; the virus withstands up to 20 cycles without appreciable loss of titer [1]. This property is invaluable for research aliquoting and for the creation of master and working virus banks, where multiple freeze-thaw events are unavoidable. The mechanism underlying this cryo-resistance likely involves the virus's robust lipid envelope and the stabilizing effect of the internal core proteins, though the addition of cryoprotectants like recombinant human serum albumin (rHSA) has been shown to further reduce inactivation during these processes [1].

In stark contrast to its thermal and cryo-stability, ORFV displays a nuanced sensitivity to mechanical forces. The virus exhibits low shear sensitivity when subjected to the forces generated by peristaltic pumps and standard mixing operations [1]. This is a critical finding for process engineers, as it validates the use of common fluid-handling equipment in bioreactor systems and transfer lines without the need for specialized, low-shear impellers. However, the virus is highly sensitive to ultrasonication, a technique often employed for cell lysis or particle dispersion [1]. The cavitation forces and localized heating generated by ultrasonication are sufficient to disrupt the viral envelope, leading to rapid and complete inactivation. This sensitivity necessitates the avoidance of ultrasonic-based steps in any ORFV production protocol and highlights the importance of using gentle, membrane-based or hydrodynamic cavitation-free methods for clarification and processing.

Inactivation Strategies and Implications for Biosafety

Understanding the inactivation profile of ORFV is paramount for both laboratory biosafety and the development of killed vaccine candidates. While the virus is not classified as a high-risk pathogen (BSL-2), its zoonotic nature and ability to cause self-limiting but painful lesions in humans necessitate robust inactivation protocols for waste streams and product safety [4, 10, 29]. The stability data provide a roadmap for effective inactivation. The virus's sensitivity to acidic conditions below its pI (pH 3.5) suggests that low-pH incubation could serve as an effective inactivation method [1]. Similarly, the destabilizing effect of NH₄Cl, while not a standard virucidal agent, points to the potential of disrupting viral integrity through osmotic or chemical means [1]. Standard chemical inactivants used for enveloped viruses, such as beta-propiolactone (BPL) or formaldehyde, are expected to be highly effective against ORFV, though specific kinetic data from the provided sources are limited. The sensitivity to ultrasonication also provides a physical method for complete inactivation in laboratory settings [1]. The presence of infectious ORFV in the saliva and milk of asymptomatic goats, as well as its potential mechanical transmission by insects like Musca domestica, underscores the need for stringent biosecurity and inactivation of contaminated materials in both research and production environments [2, 6].

Pharmaceutical Production: Downstream Processing and Formulation

The translation of ORFV stability data into a scalable, GMP-compliant manufacturing process has been a major focus of recent research. The development of a robust downstream process (DSP) is critical for removing host-cell DNA, proteins, and other process-related impurities while maintaining high viral infectivity yields. A complete, scalable DSP for cell culture-derived ORFV has been established, comprising a membrane-based clarification step, a nuclease (e.g., Benzonase) treatment to digest residual host-cell DNA, and a two-step chromatographic purification train [39]. The clarification step, which removes cell debris, achieves recoveries exceeding 70% [39].

The core of the purification strategy relies on chromatography. Steric exclusion chromatography (SXC) has emerged as a highly effective capture step, leveraging the large size of the ORFV particle (approximately 260 nm by 160 nm) to exclude it from the pores of a hydrophilic stationary phase in the presence of high concentrations of polyethylene glycol (PEG). This method yields recoveries of up to 84% and provides excellent removal of smaller protein impurities [7, 39]. A secondary polishing step using Capto™ Core 700 resin, which combines size exclusion with multimodal ligand binding, further purifies the virus and removes residual contaminants. This combined chromatography train achieves step recoveries of over 90% and results in a final product with protein concentrations below detection limits and a DNA concentration of approximately 1 ng per 1×10⁶ infective virus units, representing a total DNA depletion of 96–98% [39]. The process has been validated for two different ORFV genotypes, demonstrating its broad applicability [39].

The formulation of the final drug product is guided by the stability data. The use of a buffer within the pH 5.0–7.4 range, such as PBS or TRIS, is recommended [1]. The inclusion of a stabilizer is critical for long-term storage. Recombinant human serum albumin (rHSA) has been specifically identified as a potent stabilizer, reducing virus inactivation during processing and storage [1]. The low shear sensitivity of ORFV allows for the use of standard filling and packaging equipment. The final formulated product, whether intended for intramuscular, subcutaneous, or intradermal administration, must be a sterile, isotonic solution that preserves the infectivity of the viral vector, which is essential for its ability to infect host cells, express transgenes, and elicit a potent immune response [9, 12, 28]. The combination of a well-defined stability profile and a high-yield, scalable purification process positions the ORFV platform for successful commercial and clinical translation.

Prevention, Control, and Vaccine Development for Orf Virus

The prevention and control of Orf virus (ORFV) present a unique and multifaceted challenge to veterinary medicine, public health, and the global livestock industry. Unlike many viral pathogens that confer lifelong immunity upon recovery, ORFV is notorious for its capacity to reinfect both previously infected and vaccinated hosts, a phenomenon deeply rooted in the virus’s sophisticated repertoire of immunomodulatory genes [3, 15, 18]. Consequently, a comprehensive control strategy cannot rely on a single intervention but must integrate robust biosecurity protocols, rapid and accurate diagnostics, enhanced surveillance, and the strategic deployment of next-generation vaccines. The economic burden of ORFV, recognized by the World Organization for Animal Health (WOAH) as a significant constraint on small ruminant production, is compounded by its zoonotic potential, necessitating a One Health approach that bridges veterinary and human medicine. This section provides an exhaustive analysis of the current state and future directions of ORFV prevention, control, and vaccine development.

Biosecurity and Husbandry Practices: The First Line of Defense

Effective control of ORFV hinges on breaking the chain of transmission within and between herds. The virus is remarkably stable in the environment, particularly within dried scabs, which can remain infectious for years [15, 18]. This environmental persistence mandates rigorous biosecurity measures. Quarantine protocols for newly introduced animals are critical, as subclinical carriers can shed infectious virus in saliva and milk without displaying overt clinical signs [2, 19]. The detection of ORFV in the saliva and milk of asymptomatic dairy goats represents a paradigm shift in understanding transmission dynamics, indicating that apparently healthy animals can serve as reservoirs, silently perpetuating the virus within a flock [2]. This finding underscores the insufficiency of relying solely on clinical inspection and reinforces the need for routine molecular surveillance in endemic regions.

Vector-borne transmission adds a further layer of complexity. Experimental evidence has demonstrated that the common housefly (Musca domestica) can mechanically acquire and transmit ORFV DNA to contact surfaces, with 60% of flies testing positive for viral DNA in their crop and excreta [6]. This implicates these insects as potential mechanical vectors, particularly in intensive management systems where high animal density and poor sanitation create ideal breeding grounds. Therefore, integrated pest management, including proper manure disposal and fly control, should be a standard component of ORFV control programs [6].

Husbandry practices themselves are a major risk factor. Studies in Malaysia, where compliance with Herd Health Program (HHP) components was alarmingly low, with milking management showing the worst compliance at -82.69%, correlated directly with a high seroprevalence of 22.8% [14]. This demonstrates that a breakdown in basic management, such as poor hygiene during milking, can dramatically increase transmission. Furthermore, the practice of introducing animals to shared grazing land, particularly in alpine regions, facilitates the spillover of ORFV from domestic sheep to wildlife populations, such as chamois, creating a sylvatic cycle that complicates eradication efforts [17, 27]. Control measures must therefore be tailored to the specific epidemiological context, considering factors like species, age, sex, and management system, as these have all been statistically associated with infection risk [14, 20].

Surveillance, Rapid Detection, and the Role of Wildlife

Early and accurate diagnosis is the cornerstone of any effective disease control program. The clinical presentation of ORFV in small ruminants, proliferative scabby lesions on the lips, nostrils, and udder, can be pathognomonic in endemic areas, but laboratory confirmation is essential for differentiating it from other vesicular diseases and for detecting subclinical infections. The development of rapid, field-deployable molecular diagnostics has been a major advance. Isothermal amplification techniques, such as recombinase polymerase amplification (RPA) and loop-mediated isothermal amplification (LAMP), have revolutionized point-of-care testing. RPA assays, combined with lateral flow dipsticks or fluorescent probes, can detect as few as 10–100 copies of ORFV DNA in under 25 minutes without the need for thermal cyclers, making them ideal for resource-limited settings [40, 43, 46]. Similarly, LAMP assays have been successfully adapted for on-site diagnosis in wild Japanese serows using portable cordless incubators and colorimetric indicators like hydroxy naphthol blue for visual detection by the naked eye [23]. These tools empower veterinarians and field workers to make real-time decisions regarding quarantine and culling.

Surveillance must extend beyond domestic herds to include wildlife, which act as a reservoir and sentinel for the virus. ORFV has been documented in a wide range of wild ungulates, including mountain goats, Dall's sheep, muskoxen, caribou, and Sitka black-tailed deer in Alaska, often with severe, proliferative lesions [17]. The genomic characterization of these isolates reveals that they can cluster separately from domestic strains, suggesting independent evolution or spillback events [17]. This wildlife interface is not merely an ecological curiosity; it poses a direct zoonotic risk to hunters, wildlife biologists, and subsistence harvesters who may come into contact with infected carcasses [17, 27]. The molecular epidemiology of ORFV, driven by phylogenetic analyses of genes like B2L and F1L, has revealed significant geographical and host-associated clustering. Isolates from goats and sheep often form distinct phylogenetic clades, and within a single region like China's Fujian Province, high heterogeneity exists even between neighboring farms, indicating multiple circulating viral lineages [25, 32, 37]. Understanding this genetic diversity is crucial for assessing vaccine strain match and for tracking transboundary movements of the virus, which are often poorly controlled and can introduce exotic strains into naive populations [15].

The Challenge and Evolution of Vaccination

Vaccination remains the most powerful tool for long-term disease control, but its application against ORFV has been fraught with historical difficulties. Traditional live-attenuated vaccines, derived from passaging virulent field strains in cell culture, have been the mainstay of prophylaxis for decades. While they can induce partial protection and reduce the severity of clinical disease, they are associated with significant safety concerns and efficacy limitations. The attenuated virus can retain residual virulence, causing lesions at the vaccination site and posing a risk of spreading to unvaccinated animals and even humans [3]. More critically, these vaccines fail to induce sterile immunity, allowing vaccinated animals to become infected and shed virus during outbreaks. This failure is attributed to the virus’s potent immunomodulatory arsenal, which includes a viral interleukin-10 (vIL-10) homologue (ORFV127), a chemokine binding protein (CBP; ORFV112), and a granulocyte-macrophage colony-stimulating factor/interleukin-2 inhibitor (GIF; ORFV117) [5]. These proteins actively subvert the host's Th1-type immune response, which is critical for poxvirus clearance, and promote a Th2-biased environment that is permissive to reinfection [3, 35].

Experimental deletion of these immunomodulatory genes has provided a rational path toward safer, more effective vaccines. Recombinant ORFV strains lacking individual genes, such as ORFV112, ORFV117, or ORFV127, replicate normally in cell culture but show a marked reduction in virulence in vivo, with infected lambs exhibiting faster lesion regression and reduced viral shedding from day 16 post-infection onward compared to the parental wild-type virus [5]. This proof-of-concept validates that targeted gene deletion can attenuate the virus while retaining its immunogenicity. Indeed, the attenuated vaccine strain D1701-V, which has undergone extensive genomic deletions including the loss of seven open reading frames (including ORFV117 and others), has shown an excellent safety profile and is now being successfully exploited as a viral vector platform for both veterinary and human vaccines [12].

Recombinant and Vectored Vaccine Platforms: A New Era

The limitations of conventional vaccines have driven the development of advanced platforms, with the ORFV itself emerging as a powerful viral vector. The D1701-V strain, which is apathogenic yet highly immunogenic, can be engineered to express heterologous antigens from a wide range of pathogens. This platform has demonstrated remarkable versatility. When used to express the hemagglutinin (HA) of highly pathogenic avian influenza H5N1, a single intramuscular injection in mice provided complete protection against lethal challenge, including cross-clade protection against H5N1 and heterologous H1N1 [28]. The protective immunity was dependent on CD4+ T-cells, a hallmark of a robust adaptive response [28]. Similarly, the ORFV vector has shown profound therapeutic efficacy against papillomavirus-induced tumors in rabbits. Vaccination with ORFV recombinants expressing the CRPV early proteins E1, E2, LE6, and E7 led to significant tumor growth suppression in 84.6% of treated animals, with one achieving complete and lasting regression [9]. This underscores the vector's ability to break immunological tolerance and elicit potent cellular immunity against tumor-associated antigens.

The utility of ORFV as a vector is further enhanced by its genetic plasticity. The D1701-V strain possesses multiple insertion sites, such as the deletion loci A, AT, and D, allowing for the simultaneous expression of multiple transgenes from a single recombinant virus [12]. This capability opens the door to polyvalent vaccines that can target several pathogens in a single shot. Furthermore, the identification of strong viral promoters, including the native VEGF-E promoter and synthetic early promoters like eP2, enables robust and controlled transgene expression [12].

Beyond vectored vaccines, DNA vaccine approaches are also being explored. A novel bivalent DNA vaccine fusing the major immunodominant ORFV envelope protein B2L with the neuropeptide kisspeptin-54 induced not only a strong humoral and cell-mediated immune response (characterized by elevated TNFα, IFN-γ, and IL-2) against B2L but also acted as an immunocastration agent, causing testicular atrophy and arrested spermatogenesis in rats [41]. This dual-function strategy could be particularly valuable for managing populations of free-ranging or feral animals, simultaneously controlling ORFV and reproduction. The B2L protein itself has been identified as a potent immunomodulator capable of eliciting immune cell accumulation at inoculation sites and acting as an adjuvant to enhance antigen-specific responses [31], making it a valuable component of future subunit or DNA vaccines.

Despite these advances, significant hurdles remain. The genetic and antigenic heterogeneity of circulating ORFV strains, as documented by numerous phylogenetic studies, poses a challenge to the development of broadly protective vaccines [21, 25, 30]. The short duration of immunity induced by current vaccines and the ability of ORFV to repeatedly infect vaccinated animals necessitate the development of strategies to induce durable, sterilizing immunity, perhaps through novel adjuvants or prime-boost regimens that target the viral immunomodulators directly. As the World Health Organization (WHO) and WOAH emphasize, a coordinated global surveillance network, combined with the deployment of these next-generation vaccines, is essential to mitigate the zoonotic risk and the profound economic impact of this re-emerging disease.

References

[1] Eilts F, Labisch JJ, Orbay S, Harsy YM, Steger M, Pagallies F, et al.. Stability studies for the identification of critical process parameters for a pharmaceutical production of the Orf virus.. Vaccine. 2023. DOI: https://doi.org/10.1016/j.vaccine.2023.06.047

[2] Ma W, Pang M, Lei X, Wang Z, Feng H, Li S, et al.. Orf Virus Detection in the Saliva and Milk of Dairy Goats. Frontiers in Microbiology. 2022. DOI: https://doi.org/10.3389/fmicb.2022.837808

[3] Bukar A, Jesse F, Abdullah C, Noordin M, Lawan Z, Mangga HK, et al.. Immunomodulatory Strategies for Parapoxvirus: Current Status and Future Approaches for the Development of Vaccines against Orf Virus Infection. Vaccines. 2021. DOI: https://doi.org/10.3390/vaccines9111341

[4] Thompson HJ, Harview C, Swick B, Powers J. Orf Virus in Humans: Case Series and Clinical Review.. Cutis (New York, N.Y.). 2022. DOI: https://doi.org/10.12788/cutis.0567

[5] Martins M, Rodrigues F, Joshi LR, Jardim JC, Flores M, Weiblen R, et al.. Orf virus ORFV112, ORFV117 and ORFV127 contribute to ORFV IA82 virulence in sheep.. Veterinary Microbiology. 2021. DOI: https://doi.org/10.1016/j.vetmic.2021.109066

[6] Raele D, Jr JGS, Vasco I, Pennuzzi G, Porta MCNL, Cafiero M. Study on the Role of the Common House Fly, Musca domestica, in the Spread of ORF Virus (Poxviridae) DNA under Laboratory Conditions. Microorganisms. 2021. DOI: https://doi.org/10.3390/microorganisms9112185

[7] Lothert K, Pagallies F, Feger T, Amann R, Wolff M. Selection of chromatographic methods for the purification of cell culture-derived Orf virus for its application as a vaccine or viral vector. Journal of Biotechnology. 2020. DOI: https://doi.org/10.1016/j.jbiotec.2020.07.023

[8] Sahu B, Majee P, Singh R, Sahoo A, Nayak D. Comparative analysis, distribution, and characterization of microsatellites in Orf virus genome. Scientific Reports. 2020. DOI: https://doi.org/10.1038/s41598-020-70634-6

[9] Schneider M, Müller M, Yigitliler A, Xi J, Simon C, Feger T, et al.. Orf Virus-Based Therapeutic Vaccine for Treatment of Papillomavirus-Induced Tumors. Journal of Virology. 2020. DOI: https://doi.org/10.1128/JVI.00398-20

[10] Vellucci A, Manolas MI, Jin S, Dwyer J, Vick G, Wang AR, et al.. Orf virus infection after Eid al-Adha. IDCases. 2020. DOI: https://doi.org/10.1016/j.idcr.2020.e00854

[11] Andreani J, Fongue J, Khalil JB, David L, Mougari S, Bideau ML, et al.. Human Infection with Orf Virus and Description of Its Whole Genome, France, 2017. Emerging Infectious Diseases. 2019. DOI: https://doi.org/10.3201/eid2512.181513

[12] Rziha H, Büttner M, Müller M, Salomon F, Reguzova A, Laible D, et al.. Genomic Characterization of Orf Virus Strain D1701-V (Parapoxvirus) and Development of Novel Sites for Multiple Transgene Expression. Viruses. 2019. DOI: https://doi.org/10.3390/v11020127

[13] Şevik M. Orf virus circulation in cattle in Turkey.. Comparative Immunology, Microbiology & Infectious Diseases. 2019. DOI: https://doi.org/10.1016/J.CIMID.2019.03.013

[14] Bala J, Balakrishnan K, Abdullah A, Adamu L, Noorzahari MSB, May LK, et al.. An association of Orf virus infection among sheep and goats with herd health programme in Terengganu state, eastern region of the peninsular Malaysia. BMC Veterinary Research. 2019. DOI: https://doi.org/10.1186/s12917-019-1999-1

[15] Bala J, Balakrishnan K, Abdullah A, Mohamed R, Haron A, Jesse F, et al.. The re-emerging of orf virus infection: A call for surveillance, vaccination and effective control measures.. Microbial Pathogenesis. 2018. DOI: https://doi.org/10.1016/j.micpath.2018.04.057

[16] Wang Y, Yang K, Z Y, Zhang Q, Zhang G, L S, et al.. Identification and phylogenetic analysis of an orf virus strain isolated in Anhui Province, East-central China, in 2018.. Acta virologica. 2019. DOI: https://doi.org/10.4149/av_2019_304

[17] Tryland M, Beckmen K, Burek‐Huntington K, Breines E, Klein J. Orf virus infection in Alaskan mountain goats, Dall’s sheep, muskoxen, caribou and Sitka black-tailed deer. Acta Veterinaria Scandinavica. 2018. DOI: https://doi.org/10.1186/s13028-018-0366-8

[18] Wang R, Wang Y, Liu F, Luo S. Orf virus: A promising new therapeutic agent. Reviews in Medical Virology. 2018. DOI: https://doi.org/10.1002/rmv.2013

[19] Cheng H, Li W, Li X, Fan Q, Tang X, Liu M, et al.. Pathogenicity of blood orf virus isolates in the development of dairy goat contagious pustular dermatitis.. Veterinary Microbiology. 2018. DOI: https://doi.org/10.1016/j.vetmic.2018.04.020

[20] Tedla MG, Berhan N, Molla W, Temesgen W, Alemu S. Molecular identification and investigations of contagious ecthyma (Orf virus) in small ruminants, North west Ethiopia. BMC Veterinary Research. 2018. DOI: https://doi.org/10.1186/s12917-018-1339-x

[21] Gelaye E, Achenbach J, Jenberie S, Ayelet G, Belay A, Yami M, et al.. Molecular characterization of orf virus from sheep and goats in Ethiopia, 2008–2013. Virology Journal. 2016. DOI: https://doi.org/10.1186/s12985-016-0489-3

[22] Hsu CH, Rokni GR, Aghazadeh N, Brinster N, Li Y, Muehlenbachs A, et al.. Unique Presentation of Orf Virus Infection in a Thermal-Burn Patient After Receiving an Autologous Skin Graft. Journal of Infectious Diseases. 2016. DOI: https://doi.org/10.1093/infdis/jiw307

[23] Inoshima Y, Takasu M, Ishiguro N. Establishment of an on-site diagnostic procedure for detection of orf virus from oral lesions of Japanese serows (Capricornis crispus) by loop-mediated isothermal amplification. Journal of Veterinary Medical Science. 2016. DOI: https://doi.org/10.1292/jvms.16-0268

[24] Fleming S, Wise LM, Mercer A. Molecular Genetic Analysis of Orf Virus: A Poxvirus That Has Adapted to Skin. Viruses. 2015. DOI: https://doi.org/10.3390/v7031505

[25] Chi X, Zeng X, Li W, Hao W, Li M, Huang X, et al.. Genome analysis of orf virus isolates from goats in the Fujian Province of southern China. Frontiers in Microbiology. 2015. DOI: https://doi.org/10.3389/fmicb.2015.01135

[26] Joseph R, Haddad FA, Matthews A, Maroufi A, Monroe B, Reynolds MG. Erythema multiforme after orf virus infection: a report of two cases and literature review. Epidemiology and Infection. 2014. DOI: https://doi.org/10.1017/S0950268814000879

[27] Kitchen M, Müller H, Zobl A, Windisch A, Romani N, Huemer H. ORF virus infection in a hunter in Western Austria, presumably transmitted by game.. Acta Dermato-Venereologica. 2014. DOI: https://doi.org/10.2340/00015555-1643

[28] Rohde J, Amann R, Rziha H. New Orf Virus (Parapoxvirus) Recombinant Expressing H5 Hemagglutinin Protects Mice against H5N1 and H1N1 Influenza A Virus. PLoS ONE. 2013. DOI: https://doi.org/10.1371/journal.pone.0083802

[29] Nougairède A, Fossati C, Salez N, Cohen-Bacrie S, Ninove L, Michel F, et al.. Sheep-to-Human Transmission of Orf Virus during Eid al-Adha Religious Practices, France. Emerging Infectious Diseases. 2013. DOI: https://doi.org/10.3201/eid1901.120421

[30] Zhang K, Liu Y, Kong H, Shang Y, Liu X. Comparison and phylogenetic analysis based on the B2L gene of orf virus from goats and sheep in China during 2009-2011. Archives of Virology. 2013. DOI: https://doi.org/10.1007/s00705-013-1946-6

[31] Mcguire M, Johnston S, Sykes K. Novel immune-modulator identified by a rapid, functional screen of the parapoxvirus ovis (Orf virus) genome. Proteome Science. 2012. DOI: https://doi.org/10.1186/1477-5956-10-4

[32] Li W, Ning Z, Hao W, Song D, Gao F, Zhao K, et al.. Isolation and phylogenetic analysis of orf virus from the sheep herd outbreak in northeast China. BMC Veterinary Research. 2012. DOI: https://doi.org/10.1186/1746-6148-8-229

[33] Emschermann F, Knittler M, Rziha H. Orf virus interferes with MHC class I surface expression by targeting vesicular transport and Golgi. BMC Veterinary Research. 2012. DOI: https://doi.org/10.1186/1746-6148-8-114

[34] Wise LM, Bodaan C, Stuart GS, Real N, Lateef Z, Mercer A, et al.. Treatment of limb wounds of horses with orf virus IL-10 and VEGF-E accelerates resolution of exuberant granulation tissue, but does not prevent its development. PLoS ONE. 2018. DOI: https://doi.org/10.1371/journal.pone.0197223

[35] Wang R, Luo S. Orf Virus: A New Class of Immunotherapy Drugs. Systems Biology. 2018. DOI: https://doi.org/10.5772/INTECHOPEN.81535

[36] Chen D, Long M, Xiao B, Xiong Y, Chen H, Chen Y, et al.. Transcriptomic profiles of human foreskin fibroblast cells in response to orf virus. OncoTarget. 2017. DOI: https://doi.org/10.18632/oncotarget.17417

[37] Chi X, Zeng X, Hao W, Li M, Li W, Huang X, et al.. Heterogeneity among Orf Virus Isolates from Goats in Fujian Province, Southern China. PLoS ONE. 2013. DOI: https://doi.org/10.1371/journal.pone.0066958

[38] Billinis C, Mavrogianni VS, Spyrou V, Fthenakis G. Phylogenetic analysis of strains of Orf virus isolated from two outbreaks of the disease in sheep in Greece. Virology Journal. 2012. DOI: https://doi.org/10.1186/1743-422X-9-24

[39] Lothert K, Pagallies F, Eilts F, Sivanesapillai A, Hardt M, Moebus A, et al.. A scalable downstream process for the purification of the cell culture-derived Orf virus for human or veterinary applications.. Journal of Biotechnology. 2020. DOI: https://doi.org/10.1016/j.jbiotec.2020.08.014

[40] Wang Y, Cui Y, Yu Z, Li Y, Bai C, Sun P, et al.. Development of a recombinase-aided amplification assay for detection of orf virus.. Journal of Virological Methods. 2020. DOI: https://doi.org/10.1016/j.jviromet.2020.113861

[41] Wassie T, Fanmei Z, Jiang X, Liu G, Girmay S, Min Z, et al.. Recombinant B2L and Kisspeptin-54 DNA Vaccine Induces Immunity Against Orf Virus and Inhibits Spermatogenesis In Rats. Scientific Reports. 2019. DOI: https://doi.org/10.1038/s41598-019-52744-y

[42] Wang Y, Yang K, Bai C, Yin D, Li G, Qi K, et al.. Development of a SYBR Green I real-time PCR for the detection of the orf virus. AMB Express. 2017. DOI: https://doi.org/10.1186/s13568-016-0322-9

[43] Yang Y, Qin X, Wang G, Jin J, Shang Y, Zhang Z. Development of an isothermoal amplification-based assay for rapid visual detection of an Orf virus. Virology Journal. 2016. DOI: https://doi.org/10.1186/s12985-016-0502-x

[44] Maganga G, Relmy A, Bakkali-Kassimi L, Ngoubangoye B, Tsoumbou T, Bouchier C, et al.. Molecular characterization of Orf virus in goats in Gabon, Central Africa. Virology Journal. 2016. DOI: https://doi.org/10.1186/s12985-016-0535-1

[45] Mwanandota JJ, Macharia M, R. MCA, Sallu R, Yongolo M, Holton TA. Phylogenetic Analysis of ORF Virus from Goats in Tanzania: Short Communication. Universal Journal of Agricultural Research. 2016. DOI: https://doi.org/10.13189/UJAR.2016.040501

[46] Yang Y, Qin X, Wang G, Zhang Y, Shang Y, Zhang Z. Development of a fluorescent probe-based recombinase polymerase amplification assay for rapid detection of Orf virus. Virology Journal. 2015. DOI: https://doi.org/10.1186/s12985-015-0440-z